Affiliations 

  • 1 Jamalul Azizi Abdul Rahaman Consultant Pulmonologist, Hospital Serdang, Malaysia
  • 2 Ker Hong Bee Consultant Infectious Disease Physician, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia
  • 3 Mohd. Aminuddin Mohd. Yusof (Corresponding author) Head, CPG Unit, Health Technology Assessment Section, Ministry of Health, Malaysia Emial: am2dr@yahoo.com
  • 4 Nik Sherina Hanafi Primary Care Physician, Department of Primary Care Medicine, University of Malaya, Malaysia
  • 5 Wong Jyi Lin Respiratory Physician, Hospital Umum Sarawak, Kuching, Malaysia
Malays Fam Physician, 2014;9(3):34-7.
PMID: 26425303 MyJurnal

Abstract

Tuberculosis (TB) in Malaysia is rising due to multiple factors and issues related to its management are addressed in the updated evidence-based clinical practice guidelines. Screening for active TB should be considered in high risk groups. Light emitting diode-based fluorescence microscopy and nucleic acid amplification tests are recommended investigations. Health education and standardised 6-month daily antituberculosis (antiTB) regimen are among important elements for successful treatment. Latent TB infection screening should only be performed on high risk individuals. AntiTB regimen offered to HIV-positive adults should be the same as for HIV-negative adults and timing to initiate highly active antiretroviral therapy in patients with TB is based on CD4 count. All patients on antiTB treatment should be monitored to assess their response to treatment and to identify problems associated with it.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.